Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review
- PMID: 33065425
- DOI: 10.1016/j.semarthrit.2020.08.010
Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review
Abstract
Background: Non-infectious non-anterior uveitis (NINA) is a sight-threatening condition that often requires immunomodulatory drugs (IMDs) for its management.
Objectives: To evaluate the published evidence regarding the use of IMDs in adult patients with NINA uveitis including intermediate (IU) and posterior uveitis (PU), panuveitis (PanU) and macular edema (ME).
Methods: We performed a systematic literature review. Search strategies were designed for Medline, Embase, and Cochrane Libraries for articles up to 2019 to evaluate the efficacy and safety of the IMDs. A quality assessment was performed using the Jadad Scale.
Results: Nineteen randomized clinical trials were selected from the 1,103 articles retrieved. Characteristics of patients, treatment dosages and outcome measures were heterogeneous. The outcomes most frequently analyzed were visual acuity (VA), macular thickness and vitreous haze (VH). Different IMDs were used at their usual dosages. Methotrexate (MTX), micophenolate mofetil, cyclosporine A (CsA), tacrolimus, adalimumab and sarilumab were effective in NINA uveitis. Rituximab combined with MTX was effective in PU. Interferon-β was superior to MTX, albeit with more adverse events in IU with ME. CsA was similar to cyclophosphamide (Cyc) in Behçet uveitis. Tacrolimus was safer and similar to CsA. Cyc was effective in serpiginoid choroiditis, but when combined with azathioprine in PU, but did not improve VA. Secukinumab did not prevent NINA uveitis recurrences, although intravenously it showed a higher response rate than when used subcutaneously. Daclizumab did not show any benefits in Behçet NINA uveitis.
Conclusion: Several IMDs and their combinations can be useful in treating NINA uveitis. The available studies were heterogeneous regarding patient characteristics and outcomes.
Keywords: Immunomodulators; Intermediate uveitis; Macular edema; Panuveitis; Posterior uveitis; Systematic literature review.
Copyright © 2020. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.Ophthalmology. 2021 Jun;128(6):899-909. doi: 10.1016/j.ophtha.2020.10.036. Epub 2020 Nov 3. Ophthalmology. 2021. PMID: 33157077 Clinical Trial.
-
Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU):: The Phase 2 SATURN Study.Ophthalmology. 2019 Mar;126(3):428-437. doi: 10.1016/j.ophtha.2018.09.044. Epub 2018 Oct 11. Ophthalmology. 2019. PMID: 30316888 Clinical Trial.
-
Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.Ophthalmology. 2015 Oct;122(10):1967-75. doi: 10.1016/j.ophtha.2015.06.042. Epub 2015 Aug 20. Ophthalmology. 2015. PMID: 26298715 Free PMC article. Clinical Trial.
-
Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet's disease associated uveitis: a systematic review.Rheumatol Int. 2019 Jan;39(1):47-58. doi: 10.1007/s00296-018-4193-z. Epub 2018 Nov 12. Rheumatol Int. 2019. PMID: 30421105
-
Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis.Med Clin (Barc). 2020 Sep 11;155(5):220.e1-220.e12. doi: 10.1016/j.medcli.2019.10.023. Epub 2020 Mar 19. Med Clin (Barc). 2020. PMID: 32199631 English, Spanish.
Cited by
-
Therapeutic Response After Immunosuppressive Drug Prescription in Non-infectious Uveitis: A Survival Analysis.Ophthalmol Ther. 2023 Feb;12(1):139-153. doi: 10.1007/s40123-022-00587-8. Epub 2022 Oct 20. Ophthalmol Ther. 2023. PMID: 36266560 Free PMC article.
-
Update on the Management of Uveitic Macular Edema.J Clin Med. 2021 Sep 14;10(18):4133. doi: 10.3390/jcm10184133. J Clin Med. 2021. PMID: 34575244 Free PMC article. Review.
-
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive Strategies.Med Sci Monit. 2024 May 7;30:e943240. doi: 10.12659/MSM.943240. Med Sci Monit. 2024. PMID: 38711247 Free PMC article. Review.
-
Cannabinoid-Based Ocular Therapies and Formulations.Pharmaceutics. 2023 Mar 27;15(4):1077. doi: 10.3390/pharmaceutics15041077. Pharmaceutics. 2023. PMID: 37111563 Free PMC article. Review.
-
Impact of Brightness on Choroidal Vascularity Index.J Clin Med. 2024 Feb 10;13(4):1020. doi: 10.3390/jcm13041020. J Clin Med. 2024. PMID: 38398333 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical